Re-Examining the Treatment of Lead-Exposed Children Trial

The Treatment Gap

Design, Power, and Assumptions

The Treatment of Lead-Exposed Children (TLC) trial was a landmark randomized, double-blind, placebo-controlled study conducted between 1994 and 2003, funded by the National Institute of Environmental Health Sciences and the Office of Research on Minority Health. The trial investigated whether succimer (meso-2,3-dimercaptosuccinic acid), the first oral FDA-approved lead chelating agent, could prevent cognitive decline in toddlers with moderate lead poisoning — at the time defined as blood lead levels (BLLs) of 20–44 µg/dL.

In 2001, the primary results were published in the New England Journal of Medicine, reporting that although succimer significantly lowered BLLs in the short term, no long-term increase in IQ was detected. Investigators concluded that since they had failed to detect a neuropsychological effect from treatment, the drug should not be prescribed in children with BLLs <45 µg/dL.

This conclusion fundamentally reshaped clinical practice and policy. Federal agencies including the CDC and American Academy of Pediatrics quickly adopted guidelines abandoning medical treatment in favor of prevention-only approaches. By 2004, state Medicaid programs had begun refusing reimbursement for succimer below 45 µg/dL. A 2019 USPSTF systematic review rated TLC as the only good-quality study among seven RCTs evaluating interventions for elevated BLLs.

Clinical Equipoise in the Management of Lead-Exposed Children

Clinical guidance regarding the management of lead-exposed children was largely based on guidance from the CDC (1985) and the American Academy of Pediatrics (1987). These statements recommended initiating chelation therapy in children with BLLs >55 µg/dL and clinical discretion between 25 and 55 µg/dL — a range which directly reflected the CDC's definition of an elevated BLL (≥25 µg/dL). However, by 1990, new research showed IQ loss occurred as low as 10 µg/dL, raising concerns among clinicians as to whether the current recommended thresholds for intervention were sufficiently protective.

The three primary pharmacological agents in use at the time — dimercaprol (BAL), calcium disodium EDTA, and D-penicillamine — each carried unique risks that were gradually coming to light. The 1985 CDC statement identified succimer (DMSA) as a promising new, but unapproved, oral chelator. A 1990 HRSA-funded national survey revealed widespread variability in treatment thresholds at levels as low as 20 µg/dL; succimer was utilized by only one participating clinic as it awaited FDA approval.

Medicaid Reform, FDA Approval, and the 1991 Convergence

Starting January 1, 1991, the Medicaid Drug Rebate Program came into effect: state Medicaid programs were legally required to cover any FDA-approved drug if a manufacturer signed a rebate agreement, including off-label uses supported by major medical compendia. On January 30, 1991, the FDA granted final marketing approval of succimer as an orphan drug for lead poisoning in children with BLLs >45 µg/dL, with seven years of market exclusivity.

In October 1991, the CDC released "Preventing Lead Poisoning in Young Children," with three consequential moves: it lowered the chelation line from 55 to 45 µg/dL (aligning guidance with succimer's approved indication); lowered the BLL of concern to 10 µg/dL (a level shared by an estimated 1.7 million children); and recommended universal screening for every 1- and 2-year-old. A mandate to find a large new population of poisoned children, a legal mandate for Medicaid to pay for their treatment, and a monopoly on the only feasible oral drug converged in a single year.

The Project Officer and primary author on most of TLC's publications was Walter J. Rogan, MD — one of the first epidemiologists at NIEHS in the mid-1970s, working there until his retirement in 2014. According to his 1997 CV, he was the founding chair of the NIEHS IRB and its Chair from 1992–1993 — the period during which TLC was being planned and proposals were being screened. On June 25, 1993, the HHS Contracting Officer appointed Rogan as Project Officer and awarded the contract to the Kennedy Krieger Research Institute.

Primary Results Published in NEJM

In May 2001, the New England Journal of Medicine published the TLC trial's primary results, which found no significant difference in IQ between the succimer and placebo groups at 36 months. Within a year, the finding was absorbed into the policy apparatus that had been watching the trial since its inception.

"The results of the trial show clearly that treatment after the fact does not undo the damage among 5 year olds. We must prevent these children from being exposed in the first place." — NIEHS Director Kenneth Olden, PhD (NIEHS Newsroom, May 9, 2001)

The First Formal Guideline Closure

The CDC's Advisory Committee on Childhood Lead Poisoning Prevention (ACCLPP) published "Managing Elevated Blood Lead Levels Among Young Children" — a 200-page case-management guide. It recommended against chelation therapy for children with blood lead levels below 45 µg/dL, citing TLC as the basis. This was the first formal guideline to close the door on medical treatment for the 20–44 µg/dL range that TLC had studied.

Results Presented to ACCLPP

Walter Rogan — TLC's project officer and an ex officio member of ACCLPP for 16 years — presented the trial's results directly to the committee. He told them TLC "did not produce evidence to demonstrate that succimer is beneficial to children" and that "the findings do not support conducting another trial," describing succimer as "an expensive drug" that "resulted in symptoms in children who were previously asymptomatic." The committee received this as settled science.

AAP Guidance, Reaffirmation, and Rogan's Oral History

The American Academy of Pediatrics published "Lead Exposure in Children: Prevention, Detection, and Management" (2005), citing TLC and recommending against chelation below 45 µg/dL. Rogan — NIEHS Liaison to the AAP's Committee on Environmental Health for 36 years — was its primary author. The AAP reaffirmed the recommendation in 2016's "Prevention of Childhood Lead Toxicity." The 45 µg/dL threshold held.

The Gap Between 3.5 and 45 µg/dL

The result is a treatment gap. The CDC's current reference value is 3.5 µg/dL — the level at which a child is considered to have "elevated" blood lead. The chelation threshold is 45 µg/dL. Between those two numbers, there is no recommended medical intervention. A child with a blood lead level of 40 µg/dL — more than ten times the reference value — receives the same pharmacological treatment as a child with a level of 4: none.

This policy framework rests on a single trial — a trial that returned children to lead-contaminated homes where lead dust levels rebounded within three to six months (Campbell 2003), failed to sustain the blood lead separation it was powered to detect, never analyzed iron status as an effect modifier, withheld electronic adherence data, and never tested for treatment-by-site interactions across its four clinical centers. 628 of 780 enrolled children were exposed to lead-contaminated multivitamin supplements distributed by the trial itself (Rogan 1999); 83% of succimer-treated children required retreatment after the first course.